From April 9th to 12th, 2026, the 93rd China International Medical Equipment Fair (CMEF) was held at the National Convention and Exhibition Center in Shanghai. The exhibition spanned 320,000 square meters and attracted nearly 5,000 global brand exhibitors, welcoming over 300,000 professional visitors. The event focused on new trends in smart healthcare, gathering global innovations in medical technology. Three leading industry companies—Deepwise, Royal Philips NV, and Cofoe Medical Technology Co., Ltd.—presented their AI-native full-scenario solutions, platform-based innovation ecosystems, and new intelligent home medical devices, showcasing the leap in Chinese medical AI from single-point tools to full-process system empowerment.
Deepwise: Scenario-Driven, Comprehensive Empowerment Deepwise launched the country's first multimodal, full-process, integrated software and hardware intelligent solution for breast disease diagnosis, treatment, and management at this CMEF, marking the transition of medical AI from single-point assistance to system-level empowerment. Centered on breast cancer diagnosis and treatment, the solution covers the entire chain from screening and evaluation to precise diagnosis, surgical treatment, post-operative recovery, and research management. According to Deepwise, its Deepwise MetAI X imaging large model platform and Deepwise TrioData X text large model platform provide dual-platform support, integrating AI image analysis, intraoperative margin assessment, and a full-cycle patient management system. Specifically, the breast X-ray AI system is optimized for the dense breast characteristics of Chinese women, enabling automatic identification of micro-lesions; the AI-MDT system generates personalized treatment plans using multi-dimensional patient data; intraoperative real-time imaging scans assess margin status to reduce the risk of secondary surgery; and post-operative bone density monitoring is linked to endocrine therapy side-effect management. Qiao Xin, co-founder and CEO of Deepwise, stated at the exhibition, "Medical AI is currently transitioning from an efficiency tool to a clinical partner, with full-process integration into the diagnostic and treatment chain being the core focus of the next phase."
Philips: AI and Platform Innovation, Focusing on Full Spectrum of High-Incidence Diseases Royal Philips NV had its largest exhibition scale to date at this event, with a 1,000-square-meter booth showcasing dozens of innovative products. It also debuted an "Innovation Future Lab," highlighting forward-looking solutions set to launch within the next three years and outlining the evolution path from R&D to clinical application. The exhibition featured seven core zones presenting over 50 innovative products and solutions, more than 20 of which were deeply empowered by AI, covering the entire diagnosis and management process for high-incidence diseases such as cardiovascular, neurological, oncology, and sleep respiratory conditions. During the event, Philips unveiled over a dozen major innovations, including: the global debut of the Innovation AI³ super-brain platform, which embeds AI into the full magnetic resonance imaging workflow, tripling scan speed while ensuring image authenticity and improving the detection capability for micro-lesions by 65%; the China debut of the Azurion S all-domain AI smart catheterization lab, enabling 0.1-millisecond posture adjustments, reducing radiation dose by up to 83%, and increasing surgical efficiency by 17%, redefining treatment standards with an open, integrated AI intervention ecosystem; and the China debut of Deep CT, which uses clinically applied AI deep learning to provide high-definition, low-dose, high-efficiency full-domain low-noise thin-layer images, enhancing diagnostic capabilities at the primary care level. Additionally, the world's first metabolic CT, Meta CT, advances medical imaging from traditional structural diagnosis to metabolic characterization, providing key support for early cancer screening and precise identification of neurodegenerative diseases like Alzheimer's and Parkinson's; EPIQ CVx Transcend, equipped with eight cardiovascular-specific AI tools, upgrades ultrasound from a basic imaging tool to an integrated platform for precise diagnosis and intervention guidance. Philips' local innovations were particularly notable. The industry's first AI-enabled simulation positioning CT, Rembra RT, developed by Philips' Shenyang Innovation Center and manufactured at its Suzhou production base, reduces image noise by 85% and improves soft tissue contrast by 60%, providing a higher-level imaging foundation for precise tumor delineation. It will serve the global market, becoming a benchmark product that is "locally pioneered, locally benefited, and globally leading." The helium-free 1.5T MRI, developed and produced in Suzhou, has achieved 100% localization of high-end MRI product lines, with over 2,000 units installed globally, saving more than 5 million liters of helium and reducing carbon emissions by an average of 20%. At the exhibition, Philips significantly upgraded its China innovation strategy around three directions: promoting clinical value, shaping platforms, and benefiting all people. It emphasized clinical value-driven joint innovation, deep integration of AI into workflow through platform collaboration, and partnerships with local clinical experts and industry players to transform meaningful innovations into widely accessible clinical value and health benefits. Liu Ling, member of Philips' Global Executive Committee and President of Greater China, stated, "Philips will be clinically value-oriented, deeply integrate AI with platform innovation, and deepen cooperation with clinical and industry partners in the smart healthcare field, enabling more Chinese innovations to benefit China first and lead globally." Currently, Philips has established five innovation centers and five production bases in China, making the country its second-largest global market and a value engine for achieving its "2030 Impact Vision." The company aims to improve the health and well-being of 2.5 billion people annually by 2030 through technological innovation and sustainable practices.
Cofoe Partners with Meituan to Expand Instant Retail On the first day of the exhibition, Cofoe held its 2026 Spring New Product Launch, introducing five annual new products and announcing a comprehensive strategic cooperation with Meituan Healthcare, showcasing its latest developments in the smart health field. Under the theme "Further for Every Step," Cofoe launched the Xinghe II AI ventilator, a Bluetooth-connected atrial fibrillation blood pressure monitor, the X5 series bone conduction hearing aid, the Cofoe blood glucose and uric acid dual-test meter, and an H. pylori antigen test kit, further strengthening the company's technological expertise in home health devices. The new AI ventilator targets sleep respiratory health, operating with lower noise through structural optimization and noise reduction design, and uses cloud and edge AI algorithms to dynamically monitor and adaptively adjust users' breathing status. The Bluetooth-connected blood pressure monitor integrates atrial fibrillation risk screening with blood pressure monitoring, supporting cloud data synchronization and trend analysis. The bone conduction hearing aid incorporates AI environmental recognition and noise reduction technology to improve speech clarity in complex environments. These products reflect the trend of integrating AI and IoT technologies in medical devices, evolving from single functions to continuous health management tools. Zhang Zhiming, Vice Chairman of Cofoe, stated that the company will continue to align with the "Healthy China" strategy, increasing R&D investment in core algorithms, sensing technologies, and smart applications to advance the intelligent and home-based upgrade of medical devices. In terms of channel innovation, Cofoe announced a comprehensive strategic partnership with Meituan Healthcare. The two companies have previously collaborated in instant delivery, with Cofoe ranking among the top three in health instrument sales on the platform over the past year and leading in the respiratory equipment category. The upgraded cooperation will leverage Meituan's extensive instant delivery network to deeply integrate Cofoe's full range of home medical devices—including blood glucose and uric acid test strips, hearing aids, oxygen concentrators, and ventilators—into the platform, with access to services like "one-hour delivery." This aims to improve response efficiency for nighttime emergencies and chronic disease management, particularly building a one-stop elderly-friendly health闭环 for the silver-haired population in lower-tier markets. Wu Jiani, head of Meituan Healthcare's instant retail business, noted that as residents' health consumption needs continue to evolve, instant retail is becoming a key entry point for healthcare services, and the partnership is expected to enhance the accessibility of quality medical devices and better meet multi-level health demands.
At this CMEF, the three companies demonstrated the implementation paths of AI healthcare from different angles: Deepwise uses multimodal large models as a foundation to advance AI from single-point tools to full-process system empowerment; Philips integrates global resources through platform innovation, focusing on integrated diagnosis and treatment for high-incidence diseases; and Cofoe combines intelligent products with instant retail channels to deepen its presence in home health management scenarios. As AI technology increasingly integrates with medical scenarios, smart healthcare is accelerating its transition from concept to clinical practice and from hospitals to homes, injecting strong digital and intelligent momentum into the "Healthy China" initiative.
Comments